In today's match-up of The Motley Fool's Better-Buy Tournament, Celgene squares off against Freeport-McMoRan in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each other as they make the case for their stocks, with the winner determined by you, the readers.
Motley Fool analyst Max Macaluso makes the case for Celgene (NASDAQ: CELG ) , a big biotech company, to move on to the next round. After doubling in 2013, Celgene has faced a slow start to the year. However, the company's growing portfolio and pipeline make it a biotech to watch over the long term.
Motley Fool energy analyst Taylor Muckerman thinks Freeport-McMoRan Copper & Gold (NYSE: FCX ) should advance to the next round because of its foray into oil and gas. This will be its first full year with these acquired assets on its books. Couple this growth story with stable reserve valuations for copper and gold, and Freeport-McMoRan is ripe for long-term investors.
Watch these analysts square off in the following videom and then vote for a winner. Then check out the other companies in The Motley Fool's Better-Buy Bracket.
This year's winning stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Cast your vote in the poll below the video!